Attempts to obtain additional information were made with no response.The manufacturing records for onxace-27/29 sn (b)(6) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted.Onxace-27/29 sn (b)(6) was implanted (b)(6) 2016 in the aortic position of a 32-year-old male.It was replaced by an onxaap-25 aortic valved conduit on (b)(6) 2020 (3 years 299 days post-implant) in a double valve procedure with onx-32/33 implanted in the mitral position.No other information was made available.Reoperation and explantation are recognized risks associated with complications of prosthetic heart valves [ifu], but in this case we have no evidence to indicate what, if any, contribution the original on-x valve made to the decision for its removal.The event does not identify any additional hazards or modify the probability and severity of existing hazards.An on-x aortic valve was replaced with an on-x aortic valved conduit, but the reason for its removal is unknown.This report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to cryolife is accurate or has been confirmed by cryolife.
|